{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T18:58:42Z","timestamp":1704999522152},"reference-count":13,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.therap.2017.02.002","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T01:45:20Z","timestamp":1487900720000},"page":"573-578","source":"Crossref","is-referenced-by-count":7,"title":["Latent tuberculosis infection screening prior to biological treatment in Tunisian patients"],"prefix":"10.1016","volume":"72","author":[{"given":"Marwa","family":"Slouma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olfa","family":"Saidane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selma","family":"Bouden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Abdelmoula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2017.02.002_bib0070","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/rheumatology\/kes114","article-title":"Assessing the safety of biologic agents in patients with rheumatoid arthritis","volume":"5","author":"Rubbert-Roth","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.therap.2017.02.002_bib0075","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.therap.2017.02.002_bib0080","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.semarthrit.2012.07.001","article-title":"Factors influencing discrepancies between the QuantiFERON-TB gold in tube test and the tuberculin skin test in Korean patients with rheumatic diseases","volume":"42","author":"Kim","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.therap.2017.02.002_bib0085","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1136\/annrheumdis-2011-200941","article-title":"Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-\u03b3 release assays under real-life conditions","volume":"71","author":"Kleinert","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.therap.2017.02.002_bib0090","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.00028510","article-title":"The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement","volume":"36","author":"Solovic","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.therap.2017.02.002_bib0095","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/annrheumdis-2011-200489","article-title":"Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNF\u03b1 inhibitors: the utility of IFN\u03b3 assay","volume":"71","author":"Chen","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.therap.2017.02.002_bib0100","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1586\/eci.11.6","article-title":"The risk of tuberculosis in patients treated with TNF antagonists","volume":"7","author":"Salgado","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.therap.2017.02.002_bib0105","first-page":"1","article-title":"Screening for mycobacterium tuberculosis infection: questions and answers for clinical practice","volume":"1","author":"Cush","year":"2010","journal-title":"ACR Drug Safety Q"},{"key":"10.1016\/j.therap.2017.02.002_bib0110","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1136\/annrheumdis-2014-205376","article-title":"Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy","volume":"74","author":"Hatzara","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.therap.2017.02.002_bib0115","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/ard.2004.029041","article-title":"Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis","volume":"64","author":"Ponce de Le\u00f3n","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.therap.2017.02.002_bib0120","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1542-3565(04)00060-6","article-title":"High incidence of energy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy","volume":"2","author":"Mow","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.therap.2017.02.002_bib0125","first-page":"1","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"49","author":"American Thoracic Society","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.therap.2017.02.002_bib0130","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis care Res"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595717300434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595717300434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T08:11:55Z","timestamp":1554279115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595717300434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0040595717300434"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2017.02.002","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}